What is the recommended treatment with Dupixent (dupilumab) for a patient with atopic dermatitis, asthma, or chronic rhinosinusitis with nasal polyposis?

Dupilumab (Dupixent) Treatment Recommendations

Primary Recommendation

Dupilumab is the first-line biologic therapy for chronic rhinosinusitis with nasal polyps (CRSwNP), demonstrating superior efficacy across all patient-important outcomes including quality of life, nasal symptoms, polyp reduction, and sense of smell restoration. 1, 2, 3

---

FDA-Approved Indications and Dosing

Chronic Rhinosinusitis with Nasal Polyps

• Standard dosing: 300 mg subcutaneously every 2 weeks (no loading dose required) 4
• Age: Adults and pediatric patients ≥12 years 4
• Administration: Can be self-administered or given by caregiver; rotate injection sites (thigh, abdomen, or upper arm) 4

Atopic Dermatitis

• Adults: 600 mg loading dose (two 300 mg injections), then 300 mg every 2 weeks 4
• Pediatric patients 6-11 years: Weight-based dosing without loading dose 4
  • 15 to <30 kg: 300 mg every 4 weeks
  • ≥30 kg: 200 mg every 2 weeks
• Pediatric patients 6 months-5 years: Weight-based dosing every 4 weeks 4

Asthma

• Adults and pediatric ≥12 years: 400 mg or 600 mg loading dose, then 200 mg or 300 mg every 2 weeks 4
• Higher dose (600/300 mg): For oral corticosteroid-dependent asthma or comorbid moderate-to-severe atopic dermatitis or CRSwNP 4
• Pediatric 6-11 years: Weight-based dosing (no loading dose) 4

Other FDA-Approved Indications

• Eosinophilic esophagitis: Weight-based dosing for patients ≥1 year and ≥15 kg 4
• Prurigo nodularis: 600 mg loading, then 300 mg every 2 weeks 4
• COPD: 300 mg every 2 weeks 4
• Chronic spontaneous urticaria: 600 mg loading, then 300 mg every 2 weeks (adults); weight-based for pediatrics 12-17 years 4
• Bullous pemphigoid: 600 mg loading, then 300 mg every 2 weeks with tapering oral corticosteroids 4

---

Evidence for CRSwNP Superiority

Disease-Specific Quality of Life

• Dupilumab achieves the largest SNOT-22 improvement: Mean difference of -19.91 points, exceeding the minimally important difference by more than twofold 2
• Comparison to alternatives: Omalizumab produces -16.09 points; mepolizumab shows lesser benefit 2
• Clinical significance: Rhinosinusitis disease severity (VAS) decreased by -2.54 points at 4-6 months 1

Nasal Symptom Control

• Superior symptom reduction: Mean difference of -3.25 points versus -2.09 (omalizumab) and -1.82 (mepolizumab) 2
• Nasal congestion/obstruction: Decreased by -0.86 points at 4-6 months 1

Objective Disease Measures

• Nasal polyp score reduction: Mean decrease of -1.79 points at 4-6 months in patients with severe polyp disease (baseline score ~6) 1, 2
• CT scan improvements: Lund-Mackay score decreased by standardized mean difference of -1.50 at 4-6 months, sustained through 52 weeks 1, 2
• Olfactory restoration: UPSIT score improved by 10.83 points at 4-6 months, with benefits observed as early as 16 weeks 1, 2

Pulmonary Benefits in Comorbid Asthma

• FEV1 improvement: Mean difference of 0.21 liters at 4-6 months 1
• Asthma control: Significant improvement in ACQ scores regardless of baseline eosinophil count 1, 5

---

Treatment Selection Algorithm

First-Line: Dupilumab

Use dupilumab as first-line for CRSwNP patients who have failed intranasal corticosteroids for at least 4 weeks 2, 3

Specific scenarios favoring dupilumab:

• High baseline disease burden (severe symptoms, extensive polyps) 2
• Comorbid atopic dermatitis (dual indication) 2
• Comorbid asthma requiring biologic therapy 1, 5
• History of previous nasal polyp surgery 5
• NSAID-exacerbated respiratory disease (AERD) 5

Alternative Biologics: When to Consider

Omalizumab as first-line alternative:

• Female patients planning pregnancy in near future 3
• Elevated IgE levels with comorbid allergic asthma 2

Mepolizumab:

• Comorbid highly eosinophilic asthma 3
• May reduce need for revision surgery 6

---

Optimization Before Switching Biologics

If inadequate response to dupilumab after 6 months, systematically evaluate: 3

• Treatment adherence: Confirm proper injection technique and dosing schedule
• Intranasal corticosteroid continuation: Ensure ongoing use with proper technique
• Treatable traits: Assess for allergic triggers, environmental exposures, smoking
• Diagnostic accuracy: Re-evaluate diagnosis with endoscopy and imaging
• Surgical consideration: Consider revision surgery before switching biologics

---

Safety Profile

Common Adverse Events

• Most frequent: Nasopharyngitis (47% vs 33% placebo), injection site reactions (40% vs 7%), headache (20% vs 17%) 7
• Important distinction: Conjunctivitis observed in atopic dermatitis trials but NOT in CRSwNP or asthma trials 1, 2

Comparative Safety

• All approved biologics demonstrate similar low discontinuation rates due to adverse events 2
• No significant difference from placebo in overall adverse event rates (though certainty of evidence is low) 2

---

Concomitant Therapy Considerations

Intranasal Corticosteroids

• Continue during biologic therapy: Dupilumab is administered as add-on to intranasal corticosteroids 1, 7
• For atopic dermatitis: Can use with or without topical corticosteroids; reserve topical calcineurin inhibitors for problem areas (face, neck, intertriginous areas) 4

Aspirin Desensitization in AERD

• Potential additive benefit: Combining biologics with aspirin desensitization may provide superior outcomes over either alone 6
• Risk reduction: Biologics may reduce ATAD-related adverse events in high-risk patients (GI bleeding history, hypertension, diabetes) 6

---

Duration and De-escalation

Standard Treatment Duration

• Efficacy demonstrated: 16-52 weeks in clinical trials 1, 7, 5
• Long-term use: Approved for chronic maintenance therapy 4

Interval Extension (Off-Label)

• After complete resolution: Some patients maintain control with extended intervals (every 4-6 weeks) after initial disease control 8
• Important caveat: This diverges from FDA approval and current guidelines do not recommend routine de-escalation 8
• Recurrence risk: Trials demonstrate recurrence after stopping at 24 weeks; dupilumab likely has lowest recurrence rates given superior efficacy 6

---

Critical Pitfalls to Avoid

Pre-Treatment Requirements

• Complete age-appropriate vaccinations before initiating therapy 4
• Do NOT initiate biologics without adequate intranasal corticosteroid trial (minimum 4 weeks) 2, 6

Injection Technique

• Avoid injection into tender, damaged, bruised, or scarred skin 4
• Rotate injection sites with each administration 4
• For loading doses: Administer multiple injections at different sites 4

Monitoring and Expectations

• Do NOT assume equivalent evidence for all biologics: Dupilumab has the most robust data for CRSwNP 2, 3
• Baseline biomarkers may predict response: Consider eosinophil levels, IgE, and FeNO, though evidence is moderate 6
• Prior surgery may predict better outcomes: Though evidence strength is currently low 6